Zacks Research Issues Pessimistic Estimate for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Zacks Research lowered their Q2 2025 EPS estimates for Apellis Pharmaceuticals in a research note issued on Tuesday, May 27th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of ($0.46) for the quarter, down from their prior forecast of ($0.34). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals' Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.06) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.67) EPS, Q1 2027 earnings at ($0.30) EPS and FY2027 earnings at ($0.42) EPS.

A number of other analysts have also weighed in on the stock. Bank of America lowered shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $41.00 to $23.00 in a report on Friday, May 9th. Robert W. Baird decreased their target price on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Raymond James downgraded shares of Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and lowered their target price for the stock from $75.00 to $52.00 in a report on Friday, May 9th. Cantor Fitzgerald assumed coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $44.00 price objective on the stock. Finally, JPMorgan Chase & Co. increased their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Nine research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $40.05.

Apellis Pharmaceuticals Stock Performance

APLS traded up $0.20 during midday trading on Friday, reaching $19.34. The company had a trading volume of 541,537 shares, compared to its average volume of 2,294,990. The stock has a market cap of $2.43 billion, a PE ratio of -9.53 and a beta of 0.73. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The business has a 50-day moving average price of $18.82 and a two-hundred day moving average price of $25.85. Apellis Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $43.76.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The company had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company's revenue for the quarter was down 3.2% on a year-over-year basis. During the same period last year, the firm posted ($0.54) earnings per share.

Institutional Trading of Apellis Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC lifted its stake in shares of Apellis Pharmaceuticals by 1,146.2% in the 1st quarter. Acadian Asset Management LLC now owns 23,976 shares of the company's stock valued at $522,000 after purchasing an additional 22,052 shares in the last quarter. Focus Partners Wealth increased its holdings in Apellis Pharmaceuticals by 118.4% during the 1st quarter. Focus Partners Wealth now owns 21,883 shares of the company's stock worth $479,000 after purchasing an additional 11,862 shares during the last quarter. Bayforest Capital Ltd increased its holdings in Apellis Pharmaceuticals by 431.9% during the 1st quarter. Bayforest Capital Ltd now owns 52,338 shares of the company's stock worth $1,145,000 after purchasing an additional 42,499 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Apellis Pharmaceuticals by 4.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company's stock worth $4,869,000 after purchasing an additional 9,747 shares during the last quarter. Finally, Woodline Partners LP increased its holdings in shares of Apellis Pharmaceuticals by 15.5% in the 1st quarter. Woodline Partners LP now owns 218,850 shares of the company's stock valued at $4,786,000 after acquiring an additional 29,373 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company's stock.

Insider Activity

In related news, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the sale, the general counsel now directly owns 138,730 shares of the company's stock, valued at $3,482,123. This trade represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.50% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).